Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Jul 27, 2006

Title: Compounds and Processes for Single-Pot Attachment of a Label to siRNA
Number: 20060167239
Filed: Jan. 20, 2006
Lead Inventor: Paul Slattum, Mirus
The patent application, its abstract states, covers “compounds and methods … for a single-pot covalent attachment of a label to an siRNA comprising forming a covalently attachable labeling reagent for alkylating the molecule. Then, combining the covalently attachable labeling reagent with a mixture containing the molecule, under conditions wherein the labeling reagent has reactivity with the molecule thereby forming a covalent bond.”

Title: RNAi Modulation of RSV and Therapeutic Uses Thereof
Number: 20060166921
Filed: Jan. 6, 2006
Inventor: Rachel Meyers, Alnylam Pharmaceuticals
The invention “is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents,” the patent application’s abstract states. “Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.”

Title: Oligonucleotide-Based Therapeutics
Number: 20060166920
Filed: Dec. 27, 2005
Lead Inventor: Liang Xu, University of Michigan
The invention, the patent application’s abstract states, “relates to compositions comprising dsRNA. In particular, the present invention provides dsRNA comprising nucleotide sequence that is selectively complementary to bcl-xL mRNA sequence and that is not selectively complementary to bcl-xS mRNA sequence, recombinant nucleic acid comprising a vector and nucleic acid sequence for expressing bcl-xL dsRNA, pharmaceutical compositions comprising bcl-xL dsRNA, kits comprising such compositions, and methods of using the same in research, therapeutic, diagnostic, and/or drug screening applications.”

Title: RNAi Inhibition of CTGF for Treatment of Ocular Disorders
Number: 20060166919
Filed: Dec. 19, 2005
Lead Inventor: Allan Shepard, Alcon
“RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression,” the patent application’s abstract states. “Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy, and wound healing. Such disorders are treated by administering interfering RNAs of the … invention.”

Title: RNAi Modulation of MLL-AF4 and Uses Thereof
Number: 20060166918
Filed: Dec. 14, 2005
Lead Inventor: Olaf Heidenreich, Alnylam Europe
“The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides,” the patent application’s abstract states.

Title: Process for Producing siRNA
Number: 20060166913
Filed: Jan. 7, 2004 PCT Filed: Jan. 7, 2004
Inventor: Tsutomu Suzuki, University of Tokyo
The invention covers “an inexpensive and simple method for transcription and synthesis of siRNA,” the patent application’s abstract states. “The … invention provides an oligonucleotide, which at least comprises, in a direction from the 5'-terminus to the 3'-terminus: an antisense sequence of a target nucleic acid sequence; a trimming sequence which is cleaved with base-specific RNase; a sense sequence of a target nucleic acid sequence; an antisense sequence of a promoter sequence; a sequence that forms a loop; and a sense sequence of a promoter sequence, wherein the above-described antisense sequence and sense sequence of a promoter sequence form a double strand in a molecule via a hairpin structure, and when DNA is transcribed, a transcriptional product from the above-described antisense sequence and sense sequence of a target nucleic acid sequence forms a double strand in a molecule via the trimming sequence.”

Title: RNA Interference by Single-Stranded RNA Molecules
Number: 20060166910
Filed: July 10, 2003 PCT Filed: July 10, 2003
Lead Inventor: Thomas Tuschl, Max Planck
The invention “relates to sequence and structural features of single-stranded RNA molecules required to mediate target-specific nucleic acid modifications by RNA interference, such as target mRNA degradation and/or DNA methylation,” the patent application’s abstract states.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.